Uterine Serous Carcinoma
Conditions
Keywords
uterus, uterine, endometrial, endometrium, serous carcinoma, wee1, Wee-1, usc, Uterine Serous Carcinoma, serous
Brief summary
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Detailed description
This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Interventions
DRUGAzenosertib
Azenosertib is an investigational drug.
Sponsors
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Females ≥18 years of age at the time of informed consent. 2. Histologically confirmed recurrent or persistent USC for which no other proven effective treatment options are available or any available standard of care therapy was not tolerated or was refused by the subject. * Subjects with endometrial carcinoma of mixed histology where the serous component comprises at least 5% of the tumor will be considered eligible. * Subjects with carcinosarcomas (even if there is a serous component) are not eligible. 3. Measurable disease per RECIST Guideline Version 1.1 4. Required prior therapy for endometrial cancer: 1. Treatment with a platinum-based chemotherapy regimen. 2. Treatment with a PD-(L)1 inhibitor 3. Known HER2-positive tumors: Treatment with at least 1 HER2-targeted therapy, except for subjects who are not clinically eligible. 5. Adequate hematologic and organ function
Exclusion criteria
1. Any of the following treatment interventions within the specified time frame prior to C1D1: 1. Major surgery within 28 days 2. Any chemotherapy or targeted tumor therapy within 14 days or 5 half-lives (whichever is shorter). 3. Radiation therapy within 21 days; 4. Autologous or allogeneic stem cell transplant within 3 months. 5. Current use of any other investigational drug therapy \<28 days or 5 half-lives (whichever is shorter). 2. Prior therapy with ZN-c3 or any other WEE1 inhibitor, ATR inhibitor, or CHK1/2 inhibitor for USC. 3. A serious illness or medical condition(s) including, but not limited to: Any evidence of bowel obstruction as determined by air/fluid levels on computed tomography (CT) scan, recent hospitalization for bowel obstruction within 3 months prior to C1D1, or recurrent paracentesis or thoracentesis within 6 weeks prior to C1D1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency and severity of TEAEs | 2 years | To determine the safety and tolerability of ZN-c3 in subjects with recurrent or persistent USC. |
| Objective Response Rate as defined by the revised RECIST v1.1 as assessed by ICR | 2 years | To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator. | 2 years | To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules |
| Duration of Response as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator. | 2 years | To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules |
| Progression Free Survival as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator. | 2 years | To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules |
| Clinical Benefit Rate as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator. | 2 years | To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules |
| Time To Response as defined by the revised RECIST v1.1. and assessed by ICR and the Investigator. | 2 years | To investigate the antitumor activity of ZN-c3 in subjects with recurrent or persistent USC at different doses/schedules |
Countries
Australia, Canada, Georgia, United States
Outcome results
None listed